Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Jackson Memorial Hospital, 1800 NW 10 Avenue (M-820), Miami, FL, 33136, USA.
BMC Anesthesiol. 2020 Jul 20;20(1):177. doi: 10.1186/s12871-020-01095-7.
The management of Acute Respiratory Distress Syndrome (ARDS) secondary to the novel Coronavirus Disease 2019 (COVID-19) proves to be challenging and controversial. Multiple studies have suggested the likelihood of an atypical pathophysiology to explain the spectrum of pulmonary and systemic manifestations caused by the virus. The principal paradox of COVID-19 pneumonia is the presence of severe hypoxemia with preserved pulmonary mechanics. Data derived from the experience of multiple centers around the world have demonstrated that initial clinical efforts should be focused into avoid intubation and mechanical ventilation in hypoxemic COVID-19 patients. On the other hand, COVID-19 patients progressing or presenting into frank ARDS with typical decreased pulmonary compliance, represents another clinical enigma to many clinicians, since routine therapeutic interventions for ARDS are still a subject of debate.
新型冠状病毒病 2019(COVID-19)引起的急性呼吸窘迫综合征(ARDS)的治疗极具挑战性且存在争议。多项研究提示病毒引起的肺部和全身表现可能存在非典型的病理生理学机制。COVID-19 肺炎的主要悖论是严重低氧血症与肺力学正常同时存在。来自世界各地多个中心的经验数据表明,初始临床治疗应侧重于避免低氧血症 COVID-19 患者插管和机械通气。另一方面,随着疾病进展或出现典型肺顺应性下降的 ARDS 表现,对于许多临床医生来说,这是另一个临床难题,因为 ARDS 的常规治疗干预措施仍存在争议。